The FDA has granted priority review for Pfizer's PARP inhibitor talazoparib, but the drug could struggle to meet high expectations given stiff competition.
Call it an early spring surprise for Tesaro. Its closely watched cancer med niraparib—now dubbed Zejula—won an FDA nod Monday, months before its scheduled decision date.
Merck & Co. wants Medivation, too. Not content to let another Big Pharma snap up the cancer-focused biotech unchallenged, Merck has joined the fight for a prize valued at more than $10 billion.
